Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Obstetrics/Gynecology
Clinical Trials: Breast Cancer
A listing of clinical trials currently looking for volunteers to enroll in Breast Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Anniston : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Bessemer : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Birmingham : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Birmingham : Simon-Williamson Clinic, P.C.
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Birmingham : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
View More »
Birmingham : Bruno Cancer Center
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Birmingham : Univ Of Al At Birmingham Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Birmingham : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Birminghan : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Mobile : University of South Alabama
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Mobile : University of South Alabama/Mitchell Cancer Institute
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Vestavia Hills : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Anchorage : Alaska Cancer Research and Education Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Anchorage : Providence Alaska Medical Center Cancer Research
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Casa Grande : Donald W. Hill M.D., P.C. Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Chandler : Ironwood Cancer and Research Centers
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Scottsdale : Premiere Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Scottsdale : Mayo Clinic Arizona
Dose-escalation Study of Oral CX-4945
Scottsdale : Mayo Clinic Arizona Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
View More »
Scottsdale : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Tucson : Arizona Oncology Associates, PC - CASA
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Tucson : Arizona Oncology Associates, PC - HOPE
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Tucson : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Tucson : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Hot Springs : Genesis Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Fayetteville : Highlands Oncology
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Hot Springs : Genesis Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hot Springs : Genesis Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Hot Springs : Heritage Physician Group Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Jonesboro : Northeast Arkansas Clinic
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Jonesboro : Clopton Clinic
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Jonesboro : Sandoz Investigational Site Updated
Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim
Jonesboro : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Jonesboro : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Little Rock : Little Rock Hem Onc Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Little Rock : University of Arkansas for Medical Sciences
Excision Followed by Radiofrequency Ablation for Breast Cancer
Little Rock : University of Arkansas For Medical Sciences
Percutaneous Removal and Margin Ablation for Breast Cancer
Springdale : Highlands Oncology Group
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Bakersfield : Comprehensive Blood and Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Duarte : City of Hope
64 Cu-DOTA-Trastuzumab Positron Emission Tomography in Women with Advanced HER2 Positive Invasive Breast Cancer
Duarte : City of Hope
A Pilot Study Investigating the Feasibility of Using Acupuncture for the Treatment of Taxane-Induced Peripheral Neuropathy
Duarte : City of Hope
Adjuvant Therapy in Older versus Younger Women with Breast Cancer: Longitudinal Impact of Adjuvant Chemotherapy on Functional Status, Comorbidity and Quality of Life
Duarte : City of Hope
Administrative Supplement to Expand NCI-Supported Community Outreach Capacity through Community Health Educators (CHEs) of the National Outreach Network
Duarte : City of Hope
Biomarker Evaluation and Selection of Targeted Therapy (BEST-Rx)
Duarte : City of Hope
Blood Tumor Markers for Molecular Diagnosis of Breast Diseases and Monitoring of Breast Cancer Treatment and Follow-up
Duarte : City of Hope
Characterization of Circulating Tumor Cells (CTCs) to Direct Pre-Operative and Systemic Therapy in Patients with Locally Advanced or Metastatic Stage IV Breast Cancer
Duarte : City of Hope
Evaluation of Breast Cancer Patterns and Outcomes of Care
Duarte : City of Hope
Expression of P16INK4a As a Predictor of Myelosuppression in Patients with Breast Cancer
Duarte : City of Hope
Genetic Epidemiology of Breast and Ovarian Cancers
Duarte : City of Hope
Impact of Adjuvant Chemotherapy on Metabolic Syndrome Risk Factors in Breast Cancer Patients
Duarte : City of Hope
Intermittent Exemestane Therapy for Metastatic Breast Cancer
Duarte : City of Hope
Life Course Energy Balance and Breast Cancer Risk in Black/White Women Under 50
Duarte : City of Hope
Long Term Follow-Up After Breast Cancer
Duarte : City of Hope
NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Duarte : City of Hope
Objective Measures of Physical and Mental Fatigue in Women Undergoing Adjuvant Therapy for Early Stage Breast Cancer
Duarte : City of Hope
Phase I Trial of Ixabepilone and Vorinostat in Metastatic Breast Cancer
Duarte : City of Hope
PHII-96 NCI#8264: Randomized Phase II Trial of ABT-888 vs. ABT-888 in Combination with Carboplatin in Patients with Stage IV BRCA-Associated Breast Cancer
Duarte : City of Hope
Pilot Study of Secondary Causes of Osteoporosis/Osteopenia in Adults with Breast and Prostate Cancer
Duarte : City of Hope
Pro Inflammatory Cytokines and Neurobehavioral Symptoms in Women with Breast Cancer
Duarte : City of Hope
Q3Week Carboplatin with Weekly Abraxane and Trastuzumab as Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIA-IIIC) Breast Cancer BrUOG-BR-211B
Duarte : City of Hope
The Effect of Chemotherapy on Aging in Older Women with Breast Cancer as Measured by Expression of p16INK4a
Duarte : City of Hope
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older with HER2 Positive Metastatic Breast Cancer
Duarte : City of Hope
Women at Increased Breast Cancer Risk: the Decision for Prophylactic Mastectomy
Fountain Valley : Pacific Coast Hematology/Oncology Medical Group, Inc.
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Palm Springs : Palm Springs Desert Regional Medical Center - Comprehensive Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Alhambra : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Alhambra : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Anaheim : Pacific Cancer Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Anaheim : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Arcadia : Shapiro, Stafford & Yee & Polanski
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Bakersfield : TORI-Comprehensive Blood & Cancer Ctr.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Bakersfield : Comprehensive Blood and Cancer Center
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Bakersfield :
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Bakersfield : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Beverly Hills : Cedar Saini Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Beverly Hills : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Burbank : Disney Cancer Center
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Campbell : South Bay Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Campbell : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Concord : Bay Area Cancer Research Grp
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Concord : Bay Area Cancer Research Group
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Duarte : GenBasix Incorporated
Blood Sample Collection and Health Information Collection From Patients With Invasive Breast Cancer and Their Brothers and Sisters
Duarte : City of Hope
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Encinitas : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Fountain Valley : Robert A Moss-Fountain Valley
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Fountain Valley : Pacific Coast Hem/Onc
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Fresno : Cancer Care Assoc Fresno
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Fresno : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fullerton : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fullerton : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Gilroy : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Gilroy : Ronald Yanagihara MD - PP
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Gilroy : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Glendale : Glendale Memorial Hospital
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Greenbrae : California Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
La Jolla : 3855 Health Sciences Drive
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
La Jolla :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
La Jolla : University of California-San Diego - Rebecca and John Moores Cancer Center
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
La Jolla : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
La Verne : Wilshire Oncology Medical Group
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
La Verne : TORI-Wilshire Oncology Medical Group Inc.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Lancaster : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Long Beach :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Long Beach : Breastlink Med Group Inc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Long Beach : Pacific Shores Medical Group
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Long Beach : Long Beach Memorial Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Long Beach : Breastlink Medical Group, Inc
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Long Beach : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Los Angeles : Kenmar Research Institute LLC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Los Angeles : Central Hematology Oncology Medical Group
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Los Angeles : Greater Los Angeles Oncology Medical Corporation
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Los Angeles : UCLA
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Los Angeles : University of California Los Angeles
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Los Angeles : USC/Norris Comprehensive Cancer Center
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Los Angeles :
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Los Angeles : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Los Angeles : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Los Angeles : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Los Angeles : Investigational Site
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Mission Hills : North Valley Hematology/Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Montebello :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Montebello : Clin Trials & Research Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Montebello : Clinical Trials and Research Associates, Inc.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Monterey : Community Hospital of Monterey Peninsula
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Newport Beach : Hoag Memorial Hospital Presbyterian
An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging
Northridge : TORI-Thomas & Dorothy Leavey Cancer Ctr.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Northridge : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Orange : Medical Oncology Care Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Orange : Medical Oncology Care Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Orange : University of California, Irvine Medical Center Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
Oxnard : Ventura County Hematology and Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Oxnard : TORI-Ventura County Hematology-Oncology Specialists
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Oxnard : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Palm Springs : Comp Cancer Ctrs of the Desert
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Palm Springs : Comprehensive Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Pasadena : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Pomona : Swarma Chanduri, M.D.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Rancho Mirage : Access Clinical Research
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Rancho Mirage : Desert Cancer Care
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Rancho Mirage : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Redondo Beach : TORI-Cancer Care Assoc. Med. Group
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Redondo Beach : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Roseville : Sutter Roseville Medical Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Sacramento : UC Davis Cancer Center
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Sacramento : UC Davis Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Sacramento : Sutter Healthcare-Sacramento Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
San Diego : Scripps Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
San Diego : Sharp Healthcare - San Diego Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
San Francisco : UCSF Comprehensive Cancer Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
San Francisco : University of California
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
San Francisco : University of California San Francisco
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
San Francisco : University of California San Francisco
Study of Breast Cancer Prevention by Letrozole in High Risk Women
San Jose : Santa Clara Valley Medical Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
San Jose : Good Samaritan Hospital, San Jose Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
Santa Barbara : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Santa Barbara : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Santa Maria : Central Coast Medical Oncology Corporation
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Santa Maria : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Santa Monica : Premiere Oncology
Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study
Santa Monica : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Santa Rosa : Redwood Regional Medical Group, Inc.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Stanford : Stanford University - Stanford Breast Imaging Center
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
Stanford : Stanford University School of Medicine
Evaluation of the Cook Biodesign Plastic Surgery Matrix
Stanford : Stanford University School of Medicine
Phase II Gemzar, Taxol & Avastin Combination as 1st Line Tx for Metastatic Breast CA
Sylmar : Olive View UCLA Medical
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Sylmar :
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Torrance : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Valencia : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Vallejo :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
West Hollywood : Oncotherapeutics
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Westlake Village : Ashwin Kashyap MD Inc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Westlake Village : North Valley hematology/Oncology Group Inc.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Westlake Village : Trivalley Oncology Hematology
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Westlake Village : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Aurora : University of Colorado Hospital - Anschutz Cancer Pavilion
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Aurora : University of Colorado Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Denver : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Denver : Rose Medical Center
Dual-energy Contrast-enhanced (2D and 3D Mammography Versus Contrast-enhanced MRI)- A Pilot Study
Denver : Denver Health Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Denver : Rocky Mountain Canver Centers
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Denver : US Oncology - RMCC
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Denver : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fort Collins : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Grand Junction : TORI-St. Mary's Hospital Regional Cancer Ctr.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Lone Tree : Park Meadows Cosmetic Surgery
Evaluation of the Cook Biodesign Plastic Surgery Matrix
Loveland : Front Range Cancer Specialists
Dose-escalation Study of Oral CX-4945
Bridgeport : Bridgeport Hospital
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
New Haven : Yale Comprehensive Cancer Center at Yale University School of Medicine
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
New Haven : Yale University, Yale Cancer Center
Randomized Phase II Study of Preoperative Letrozole (Femara) in Combination With Avastin in Hormone Receptor Positive Breast Cancer
New Haven : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Norwich : Eastern Connecticut Hematology & Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Southington : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Stamford : Hematology/Oncology PC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Trumball : Oncology Associates of Bridgep
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Waterbury : Waterbury Hospital Health Center
Computed Tomography Laser Mammography Breast Imaging Device
Waterbury : Waterbury Hospital
Xpress Digital Mammography System Images for Computer Aided Detection Development
Daytona Beach : Halifax Medical Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Fort Lauderdale : Holy Cross Hospital
BRE 122
Fort Lauderdale : Holy Cross Hospital
CALGB 40503
Fort Lauderdale : Holy Cross Hospital
CALGB 40601
Fort Lauderdale : Holy Cross Hospital Updated New
M12-895
Fort Lauderdale : Holy Cross Hospital
MetMAB (OAM4861g )
Fort Lauderdale : Holy Cross Hospital
Nipple Sparing
Fort Lauderdale : Holy Cross Hospital
SWOG S1007
View More »
Boca Raton : Lynn Regional Cancer Center W
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Boynton Beach : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Brooksville : Pasco Hernando Oncology Associates, PA
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Clearwater : Morton Plant Mease Health Care
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Coral Springs : Northwest Hematology and Oncology Associates Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Coral Springs : Mary Beth Tomaselli
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Coral Springs : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Davie : Florida Cancer Care
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Fernandina Beach : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Fort Lauderdale : Broward Oncology Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Fort Lauderdale : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fort Myers :
Dose Escalation Study of INK128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Fort Myers : SCRI-Florida Cancer Specialist
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Fort Myers :
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Fort Myers : Investigational Site
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Ft. Lauderdale : Holy Cross Hospital
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Ft. Lauderdale :
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Ft. Myers : Florida Cancer Specialists North
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Ft. Myers : Florida Cancer Specialists South
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Gainesville : Gainesville Hem/Onc Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Gainsville : Robert R. Carroll, MD, PA - Pr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hollywood : Memorial Cancer Institute Breast Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hollywood : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Hudson : Florida Cancer Institute
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Jacksonville : Integrated Community Onc Net
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Jacksonville : Baptist Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Jacksonville : Baptist Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Jacksonville : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Jacksonville : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Jacksonville : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Jupiter : Jupiter Medical Center-Clinical Research Office
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Kissimme : Osceola Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lakeland : Lakeland Regional Cancer Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Melbourne : Osler Medical, Inc.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Miami :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Miami : Onc/Hem Group of South Florida
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Miami : University of Miami, Sylvester Comprehensive Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Miami : Advanced Medical Specialties
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Miami : Jackson Memorial Hospital
Xpress Digital Mammography System Images for Computer Aided Detection Development
New Port Richey : Florida Cancer Institute
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
New Port Richey : Pasco Hernando Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Orange Park : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Pensacola : Hope Medical Group
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Plantation : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Port St Lucie : Hem/Onc Assoc - Treasure Coast
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Port St. Lucie : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Stuart : Martin Memorial Health Systems, Stuart - Robert & Carol Weissman Cancer Center
Adjunctive Efficacy Study Of The SoftScan® Optical Breast Imaging System
Tamarac : Elizabeth Tan-Chiu, MDPA
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Tampa : Moffitt Cancer Center Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Tampa : University of South Florida Breast Cancer Program
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
West Palm Beach : Palm Beach Cancer Institute
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
West Palm Beach :
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Savannah : Memorial Health University Medical Center
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Savannah : Memorial Health University Medical Center
Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy SWOG S0715
Savannah : Memorial Health University Medical Center
ACOSOG Z1031: A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Drugs in Postmenopausal Women with Clinical Stage II/III Breast Cancer
Savannah : Memorial Health University Medical Center
Bevacizumab and Paclitaxel, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, or Ixabepilone in Treating Patients With Locally Recurrent, Stage IIIB, or Stage IV Breast Cancer
Savannah : Memorial Health University Medical Center
Capecitabine and Lapatinib With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB, Stage IIIC, or Stage IV Breast Cancer CTSU/NCCTG N0733
Savannah : Memorial Health University Medical Center
Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery NSABP B-40
Savannah : Memorial Health University Medical Center
Granisetron, Dexamethasone, Prochlorperazine, Aprepitant, and Palonosetron in Preventing Nausea in Patients Undergoing Chemotherapy for Breast Cancer URCC U1105
Savannah : Memorial Health University Medical Center
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) ECOG PACCT-1
Savannah : Memorial Health University Medical Center
Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
Savannah : Memorial Health University Medical Center
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery CALGB 40603
Savannah : Memorial Health University Medical Center
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Savannah : Memorial Health University Medical Center
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer CTSU/IBCSG 24-02
Savannah : Memorial Health University Medical Center
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer ACOSOG Z1071
Savannah : Memorial Health University Medical Center
Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer ACOSOG Z1071
Savannah : Memorial Health University Medical Center
Treatment With Pazopanib for Neoadjuvant Breast Cancer
Savannah : Memorial Health University Medical Center
Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy
Savannah : Memorial Health University Medical Center
Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement
View More »
Albany : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Athens : Northeast Georgia Cancer, LLC Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Athens : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Atlanta : Peachtree Hematology/Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Atlanta : Winship Cancer Institute at Emory University
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Atlanta : Emory University Winship Cancer Institute
Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers
Atlanta : Emory University Winship Cancer Institute
Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer
Atlanta : Emory University
Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
Atlanta : Emory University Winship Cancer Institute
Preoperative Clinical Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Triple Negative (ER-, PR-, Her2-)Early Stage Breast Cancer
Atlanta : Emory University Winship Cancer Institute
Randomized Phase II Trial of Trastuzumab or EVEROLIMUS in Hormone-refractory Metastatic Breast Cancer
Atlanta : Emory University Winship Cancer Institute
Re-expression of ER in Triple Negative Breast Cancers
Atlanta : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Atlanta : Georgia Cancer Specialists I, Pc Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Atlanta : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Atlanta : Emory University Winship Cancer Institute
Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores
Augusta : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Columbus : Amos Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Fort Gordon : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Lawrenceville : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Lawrenceville : Suburban Hem-Onc Associates
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lawrenceville : Suburban Hematology-Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lawrenceville :
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Marietta : Northwest Georgia Onc Ctrs PC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Marietta : Northwest Georgia Oncology Centers, P.C.
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Marietta : Advanced Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Marietta : Advanced Breast Care
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Marrieta : Northwest Georgia Oncology Centers, P.C.
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Honolulu : University of Hawaii Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
Coeur D Alene : North Idaho Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Meridian :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Chicago : Northwestern University
Dose finding and tolerability study of alpha-lipoic acid in patients at risk for paclitaxel induced peripheral neuropathy
Decatur : Cancer Care Specialists of Central Illinois
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Elgin : Sherman Health
CALGB 40502 A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound NAB-Paclitaxel or Ixabepilone Combined with Bevacizumab as First- Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Elgin : Sherman Health
Cognitive Function
URCC U10055: Assessment of Cognitive Function in Breast Cancer (Stg I-IIIC) & Lymphoma (intermediate or high-grade) Patients Receiving Chemo at Pre Tx, Post Tx & 6 mo follow-up.
Elgin : Sherman Health
NSABP B-46-1/USOR 07132: Phase III TC + Bevacizumab Node-Positive or Node Negative HER2 Negative Breast Cancer
Elgin : Sherman Health
NSABP B-47 A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Elgin : Sherman Health
Palpable and Operable HER2-Positive Breast Cancer
Elgin : Sherman Health
Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer
Elgin : Sherman Health
S0715, Randomized Placebo-Controlled Trial of Acetyl L-Carnitine for the Prevention of Taxane Induced Neuropathy
Elgin : Sherman Health
SWOG S0221 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node- Positive or High-Risk Node-Negative Breast Cancer
Elgin : Sherman Health
SWOG S0800: Rand Ph II Weekly Abraxane + Beva before/after Q 2 wk AC + Neulasta ? Surgery ER/PR Pos or Neg, HER2 Neg, Inflammatory Dz OR per AJCC 6th Ed. Stg IIIB (T4 N0-2), IIIA (T0-1, N2; T2N2; T3N1-2) or IIB (T2N1; T3N0) Locally Adv. PS 0-2. If HTN or > 60 yoa LVEF > ILLN MUGA/ECHO.
Elgin : Sherman Health
URCC U10054: Dbl-Blind Curcumin/Placebo PO during RT & 1 wk post RT. Noninflammatory breast ca to receive post op RT
Elk Grove Village : Alexian Brothers Hospital Network
A multicenter, open-label, randomized trial to evaluate the anti-cancer effects of zoledronic acid and circulating tumor cell measurements in patients with HER2-negative metastatic breast cancer without bone metastasis
Elk Grove Village : Alexian Brothers Hospital Network
A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
Elk Grove Village : Alexian Brothers Hospital Network
A RANDOMIZED STUDY TO PREVENT LYMPHEDEMA IN WOMEN TREATED FOR BREAST CANCER
Elk Grove Village : Alexian Brothers Hospital Network
NSABP PROTOCOL B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2-Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib to Trastuzumab and to Lapatinib Administered with Weekly Paclitaxel Following AC Accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response
Elk Grove Village : Alexian Brothers Hospital Network
NSABP PROTOCOL B-43 A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
View More »
Aurora : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Bloomingdale : Advanced Breast Care Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Chicago : University of Chicago
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
Chicago : The Robert H. Lurie Comprehensive Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Chicago : University Of Chicago Medical Center Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Chicago : Northwestern University
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Chicago : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Chicago : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Crystal Lake : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Decatur :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Decatur : Decatur Memorial Hospital Canc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Downers Grove : Good Samaritan Cancer Care Center at Advocate Good Samaritan Hospital
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Evanston : Evanston Northwestern Healthcare
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Galesburg : Medical & Surgical Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Geneva : Delnor Community Hospital - Geneva
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Harvey : Ingalls Cancer Research Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Harvey : Ingalls Memorial Hospital Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Harvey : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Highland Park : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Hinsdale : Hinsdale Hematology Onc Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Joliet : Joliet Hem/Onc Associates
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Joliet : Midwest Center for Hem/Onc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Libertyville : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Maywood :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Maywood : Cardinal Bernardin Cancer Center at Loyola University Medical Center
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Moline : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Naperville : Hem Oncology Consultants
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Naperville : Edward Hospital Cancer Center
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Naperville : Edward Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Normal : Mid-Illinois Hem & Onc Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Park Ridge : Oncology Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Peoria :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Peoria : Illinois Cancercare, Pc Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Rockford : Swedish-American Regional Cancer Center
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Skokie : Clintell, Inc.
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Skokie : Clintell - Midwest Cancer Research Group
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Skokie : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Tinley Park : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Urbana : Carle Clinic
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Winfield : Central Dupage Cancer Center
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Zion : Midwestern Regional Med Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Zion : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
New Albany : Cancer Care Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Evansville : Research Institute of Deaconess Clinic
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Fort Wayne : Fort Wayne Oncology & Hematology, Inc
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Goshen : Indiana University Health Goshen Center For Cancer Care Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Indianapolis : Investigative Clinical Research of Indiana
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Indianapolis : US Oncology - Central Indiana Cancer Centers
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Indianapolis : Indiana University Melvin and Bren Simon Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Indianapolis : Community Regional Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Indianapolis : University of Indiana
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Indianapolis : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Indianapolis : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Lafayette :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Lafayette : Horizon Oncology Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Munster : Monroe Medical Associates
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Munster : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
New Albany : Cancer Care Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
New Albany : Cancer Care Center
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Newburgh : Onc Hem Assoc of SW Indiana
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
South Bend : Northern Indiana Cancer Research Consortium
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Terre Haute : Associated Physicians and Surgeons, LLC
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Terre Haute : Providence Medical Group
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Cedar Rapids : Iowa Cancer Care
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Cedar Rapids : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Council Bluffs : Heartland Oncology and Hematol
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Iowa City : Univ of Iowa Hospitals & Clin
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Iowa City : University of Iowa Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Iowa City : University of Iowa
Xpress Digital Mammography System Images for Computer Aided Detection Development
Sioux City : Siouxland Hem-Onc Assoc LLP
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Sioux City : Siouxland Hematology-Oncology Associates, L.L.P.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Waterloo : Cedar Valley Med Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Waterloo : Cedar Valley Medical Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Hutchinson : Hutchinson Clinic PA
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Kansas City : University of Kansas Medical Center
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
Kansas City : University of Kansas Medical Center
Breast Cancer Risk Biomarkers in Postmenopausal Women
Kansas City : University of Kansas Medical Center Cancer Center
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
Kansas City : University of Kansas Medical Center
Radiofrequency Ablation After Breast Lumpectomy (ABLATE)
View More »
Kansas City : University of Kansas Medical Center
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Overland Park : Kansas City Cancer Centers
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Overland Park : Kansas City Cancer Centers
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Salina : Mowery Clinic LLC Tammy Walker Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Topeka : Cotton O'Neill Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Wichita : Cancer Center of Kansas
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Wichita : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Wichita :
Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Patients Resistant to Aromatase Inhibitor Therapy
Witchita : Cancer Center of Kansas Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Ashland : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Crestview Hills : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Danville : Commonwealth Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hazard : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Hazard : Kentucky Cancer Clinic
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Lexington : University of Kentucky
Study of Combined Fulvestrant and RAD001 in Advanced/Metastatic Breast Cancer After Aromatase Inhibitor Failure
Louisville :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Louisville : Kentuckiana Cancer Institute
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Louisville : Consultants in Blood Disorders
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Louisville : Baptist Hospital East
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Paducah : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Alexandria : Cabrini Center for Cancer Care
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Baton Rouge : Mary Bird Perkins Cancer Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Baton Rouge : Medical Oncology LLC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Baton Rouge : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Lafayette : Southwest Oncology Associates, Ltd.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Shreveport : LSUMC Feist-Weiller Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Scarborough : Maine Ctr for Cancer Medicine
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Baltimore : Cancer Center at Greater Baltimore Medical Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Annapolis : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Baltimore : St. Agnes Hospital Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Baltimore : University of Maryland/Marlene and Stewart Greenebaum Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Baltimore : The Harry and Jeannette Weinberg Cancer Institute at Franklin Square
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Baltimore : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Bethesda : Center for Cancer and Blood Disorders
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Bethesda : National Capital Clinical Research Consortium
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Bethesda : National Cancer Institute
Safety Study of MGAH22 in HER2-positive Carcinomas
Bethesda : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Clinton : Onc-Hem Associates, PA
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Columbia : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Columbia : US Oncology - Maryland Oncology
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Columbia : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Frederick : Frederick Memorial Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lanham : Signature Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Randallstown : Northwest Hospital Center Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Rockville : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Salisbury : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Boston : Investigational Site
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel, Bevacizumab, and Trastuzumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Boston : Beth Israel Deaconess Medical Center
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Boston : Dana-Farber Cancer Institute
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Boston : Faulkner Hospital
Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise After Preoperative Chemotherapy for Breast Cancer
Boston : Dana Farber Cancer Institute
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
View More »
Boston : Beth Israel Deaconess Medical Center
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Boston : Massachusetts General Hospital
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
Boston : Beth Israel Deaconess Medical Center
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Boston : Dana-Farber Cancer Institute
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Boston : Massachusetts General Hospital
Carboplatin and Bevacizumab for Progressive Breast Cancer Brain Metastases
Boston : Beth Israel Deaconess Medical Center
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Boston : Dana-Farber Cancer Institute
Extended Endocrine Therapy for Premenopausal Women With Breast Cancer
Boston : Dana Farber Cancer Institute Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Boston : Beth Israel Deaconess Medical Center Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
Boston : Dana-Farber Cancer Institute
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Boston : Dana-Farber at Faulkner Hospital
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Boston : Massachusetts General Hospital
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Boston : Dana Farber Cancer Center
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Boston : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Boston : Investigational Site
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Danvers : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Methuen : Caritas Holy Family Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Peabody : North Shore Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Pittsfield : Berkshire Hematology Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Worcester : University of Massachusetts Memorial Medical Center Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
Ann Arbor : University of Michigan Health System
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Ann Arbor : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Detroit : Karmanos Cancer Institute
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
Detroit : Henry Ford Health System/Division of Hematology/Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Detroit : Wayne State University/Karmanos Cancer Institute
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Detroit : Henry Ford Hospital Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Detroit : Karmanos Cancer Center
Safety and Pharmacokinetic Study of MM-302 in Patients With Advanced Breast Cancer
Detroit : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Detroit : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Detroit : Investigational Site
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Farmington Hills : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Flint : McLaren Regional Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Free Soil : West MI Reg Cancer & Blood Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Grand Rapids :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Grand Rapids : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Grosse Pointe : St. John Hospital and Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Holland : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Kalamazoo : Kalamazoo Hem & Onc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Kalamazoo : West Michigan Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lambertville : Hematology-Oncology Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Marquette : Marquette General Health Sys
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Petoskey : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Royal Oak : William Beaumont Hospital
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
Saint Joseph : Oncology Care Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Woodhaven : Omoh Pc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Wyoming : Metro Health Cancer Care
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Ypsilanti : Michigan Cancer Rsch Cons
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Minneapolis : The University of Minnesota Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Duluth : Duluth Clinic Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Duluth : St. Luke Whiteside Research
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Duluth : Duluth Clinic Cancer Center SMDC Health System
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Edina : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Minneapolis : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Minneapolis :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Minneapolis : Minnesota Coop Grp Outreach
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Minneapolis : Fairview Clinical Trials Services
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Minneapolis : University of Minnesota Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Minneapolis : Masonic Cancer Ctr, University Of Minnesota Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Minneapolis : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Robbinsdale : Hubert H Humphrey Cancer Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Robbinsdale : Hubert H. Humphrey Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Rochester :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Rochester : Mayo Clinic
Detection of Aggressive Breast Tumors Using Tc-99m-NC100692
Rochester : Mayo Clinic Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Saint Louis Park : Metro MN CCOP
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Saint Louis Park : Park Nicollet Institute
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
St. Louis Park : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Hattiesburg : Hattiesburg Clinic
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Jackson :
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Jackson : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
New Albany : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Pascagoula : Singing River Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Saint Louis : Washington University in St. Louis - Center for Clinical Studies
Have you had breast cancer?
View More »
Branson : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Chesterfield : St. Luke's Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Chesterfield : St. Louis Cancer Care
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Columbia : Missouri Cancer Associates
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Jefferson City : Capitol Comprehensive Cancer Care Clinic
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Kansas City : Heartland Hematology-Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Kansas City : US Oncology - Kansas City Cancer Centers
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Nixa : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Saint Louis : Mercy Hospital, St. Louis Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
Springfield : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
St Louis : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
St. Joseph : Heartland Regional Medical Center
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
St. Louis : Washington University
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
St. Louis : St. Louis Cancer & Breast Institute
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
St. Louis : The Center for Cancer Care Research
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
St. Louis : Siteman Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
St. Louis : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
St. Peters : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Billings : Billings Clinic
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Billings : Hematology Oncology Centers of the Northern Rockies
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lincoln : Nebraska Hematology Oncology,
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lincoln : Southeast Nebraska Cancer Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lincoln : Nebraska Hematology-Oncology, PC
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lincoln : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Omaha : Creighton Hematology/Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
View More »
Omaha : University of Nebraska Medical Center
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Omaha : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Henderson : Comprehensive Cancer Centers of Nevada
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Henderson : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Henderson : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Las Vegas : Comprehensive Cancer Centers of Nevada
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Las Vegas : Breast Care
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
View More »
Las Vegas : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Reno : VA Sierra NV Healthcare System
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Exeter : Exeter Hospital
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hooksett : NH Oncology-Hematology, PA
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hooksett : New Hampshire Oncology-Hematology PA
Preoperative Dose-dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Bevacizumab in Operable Breast Cancer
Lebanon : Dartmouth Hitchcock Med Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lebanon : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
View More »
Lebanon : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Livingston : St. Barnabas Medical Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Morristown : Atlantic Health System
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)
Paramus : The Valley Hospital/Valley Health System
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
View More »
Basking Ridge : Memorial Sloan-Kettering at Basking Ridge
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Belleville : Essex Oncology of North Jersey
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Cherry Hill : The Center for Cancer and Hematologic Disease
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Denville : Onc & Hematology Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Denville : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Hackensack : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Jersey City : Combined Hema/Onc Practice NJ
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Livingston : Saint Barnabas Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Long Branch : Monmouth Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Morristown : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Morristown : Hema-Onco Associates of Northe
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Morristown : Hematology Oncology Associates of Northern NJ
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Morristown : Morristown Memorial Hospital
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Morristown : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Mount Holly : Virtua Health Cancer Program
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
New Brunswick : Cancer Institute of New Jersey
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
New Brunswick : Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School
Internal Radiation Therapy of the Breast in Treating Women With Early-Stage Breast Cancer
New Brunswick : Cancer Institute of New Jersey
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
Princeton : 101 Carnegie Center
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
Somerville : Somerset Hematology Oncology Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Vineland : South Jersey Health Care
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Voorhees : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Westwood : The Valley Hospital
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Albuquerque : New Mexico Oncology Hematology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Albuquerque : Presbyterian Medical Group
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Albuquerque : University of New Mexico Cancer Care Alliance
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Albuquerque :
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Farmington :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Bronx : Biomedical Research Alliance of New York
Breast Cancer
Bronx : Biomedical Research Alliance of New York
Breast Cancer
Bronx : Our Lady of Mercy Medical Center - Comprehensive Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Jamaica : Biomedical Research Alliance of New York
HER2-positive Locally Recurrent or Metastatic Breast Cancer
Lake Success : Biomedical Research Alliance of New York
HER2-Positive Locally Advanced or Metastatic Breast Cancer - Adults
New York : Weill Cornell Breast Cancer
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Albany : New York Oncology Hematology, P.C.
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Amsterdam : US Oncology - New York Oncology Hematolgy
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Armonk : Advanced Oncology Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Binghamton : Broome Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Bronx : Eastchester Center/Cancer Care
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Bronx : Sciode Medical Associates, PLLC, d.b.a. Eastchester Center
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Bronx : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Bronx : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Bronx : Montefiore Medical Center
Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis
Brooklyn : SUNY Downstate Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Buffalo : Zale P Bernstein MD - PP
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Corning : Guthrie Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Cortlandt Manor : Ashikari Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Dunkirk : Raman Sood, MD - Private Pract
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
East Setauket : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fresh Meadows :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Fresh Meadows : Clinical Research Coordinator Queens Medical Associates, PC
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Great Neck :
A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Patients With HER2-Positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-Directed Therapy
Great Neck : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Jamaica :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Johnson City : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Kingston : Benedictine Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lake Success : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Lake Success : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Lake Success :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Lake Success : Arena Oncology Associates PC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
New Hyde Park : Arena Oncology Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
New York : Memorial Sloan-Kettering Cancer Center
Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194
New York : Memorial Sloan Kettering Cancer Center Updated
Digital Mammography for the Detection and Preoperative Staging of Breast Cancer
New York : Memorial Sloan Kettering Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
New York : Columbia University Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
New York : Beth Israel Cancer Center
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
New York : Memorial Sloan Kettering Cancer Center
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
New York : Columbia University Updated
Patient Controlled Tissue Expansion for Breast Reconstruction
New York : Beth Israel Medical Center
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
New York : Memorial Sloan-Kettering Cancer Center
Quantitative Dynamic Contrast Enhanced Breast MRI
New York : NYU Clinical Cancer Center
RAD001 Plus Carboplatin in Breast Cancer Patients
New York : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
New York : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
New York : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
New York : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Nyack : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Poughkeepsie : Vassar Brothers Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Rochester : Elizabeth Wende Breast Care
Cone Beam Computed Tomography for Breast Imaging
Rochester : Elizabeth Wende Breast Care
Cone Beam Computed Tomography for Breast Imaging
Rochester : University of Rochester/Medical Center James P. Wilmot Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Rockville Centre : Memorial Sloan-Kettering at Mercy Medical Center
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Sleepy Hollow : Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital Center
Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer
Staten Island : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Stonybrook : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Syracuse : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Asheville : Cancer Care of Western NC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Asheville : HOPE a Women's Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Asheville : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Burlington : Alamance Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Burlington : Alamance Regional Medical Center Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Charlotte : Presbyterian Hospital
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Charlotte : Presbyterian Health Care
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Charlotte : Presbyterian Hospital Cancer Research Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Concord : NorthEast Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Concord : Northeast Oncology Associates
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Concord : Northeast Oncology Associates
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Durham : Duke University
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
Durham : Duke University Medical Center
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Durham : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Durham : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Fayetteville : Carolina Cancer Management Inc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Fayetteville : Carolina Cancer Management/Cape Fear Valley Health System
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Gastonia : Gaston Hematology/Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Goldsboro : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Greensboro : Moses H Cone Memorial Hosp
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hendersonville : Hendersonville Hema & Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Hickory :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Hickory : NW Carolina Onc & Hem - ICSL
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
High Point : Emerywood Hematology Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
High Point : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Huntersville : Carolina BioOncology Inst PLLC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Raleigh : Call for Information
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM2)
Raleigh : Tolnitch Surgical Associates
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Washington :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Washington : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Winston-Salem : Piedmont Hematology Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Winston-Salem : Forsyth Regional Cancer Center
Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Winston-Salem : Wake Forest University Comprehensive Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
Bismarck : Legacy Pharma Research
Chemotherapy Induced Anemia in Patients with Metastatic Breast Cancer
View More »
Fargo :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Akron : Summa Health System/Cooper Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Barberton : Barberton Citizens Hospital-Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Canton : Aultman Hospital
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Cincinnati : MotHER Registry Coordinating Center
An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin During Pregnancy or Within 6 Months Prior to Conception
Cincinnati : Onc/Hem Care Clin Trials LLC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
View More »
Cincinnati : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Cincinnati : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Cincinnati : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Cleveland : Case Comprehensive Cancer Center - University Hospitals Case Medical Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Cleveland : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Columbus : Ohio State University
Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Columbus : Mid Ohio Oncology/Hem Inc dba
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Columbus : Hematology Oncology Cons Inc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Columbus : Hematology Oncology Consultants
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Columbus : Riverside Methodist Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Columbus : Ohio State University Medical Center
Study of Breast Cancer Prevention by Letrozole in High Risk Women
Columbus : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Columbus : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Columbus : Ohio State University
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Dayton : Dayton Clinical Oncology Prog
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Dayton : Dayton Clinical Oncology Program
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Mansfield : Ohio Cancer Specialists
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Middleton : Signal Point Clinical Research Center
Study of 0.1% Uracil Ointment (1UO) Ointment for the Prevention of Hand-Foot Syndrome
Middletown : Signal Point Clin Res Ctr LLC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Middletown : Research Site
Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Middletown : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Orange Village : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Toledo : Toledo Community Hosp Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
West Chester : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Westlake : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Wooster : Trilogy Cancer Care
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Youngstown : Forum Health Cancer Care Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Lawton : Cleo Craig Memorial Cancer
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lawton : Cancer Centers of Southwest Oklahoma
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Oklahoma City :
Dose Escalation Study of INK128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Oklahoma City : Dr. William Dooley
Randomized Study of Combination Chemotherapy With or Without Focused Microwave Thermotherapy Before Surgery in Treating Women With Large Breast Cancer Tumors
Oklahoma City : University of Oklahoma Health Sciences Center
Study of Breast Cancer Prevention by Letrozole in High Risk Women
View More »
Tulsa : Southwestern Reg Med Ctr Inc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Tulsa : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Portland : Oregon Health and Science University Hematology/Oncology
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Beaverton : Pacific Oncology, PC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Bend : Cancer Care of the Cascades
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Coos Bay : North Bend Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Springfield : Willamette Valley Cancer Institute and Research Center
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Pittsburgh : Magee Womens Hospital
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Allentown : Breast Care Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Allentown : Breast Care Specialists, P.C.
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Coudersport : Patterson Cancer Care Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Gettysburg : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Harrisburg : Pinnacle Health Fox Chase Regional Cancer Center
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Hershey :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Hershey : Cheshire Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Hershey : Hershey Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Hershey : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Hershey : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Hershey : Penn State Milton S. Hershey Medical Center
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
Lancaster : Lancaster Cancer Center Ltd
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lancaster : Lancaster General Hospital
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Lancaster : Lancaster Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Monongahela : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Philadelphia : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Philadelphia : Fox Chase Cancer Center
Exploratory, Phase I,Open Label,Non-randomized Study of [F18]CP-18 PET in Normal and Breast Cancer Subjects
Philadelphia : Thomas Jefferson University, Dept of Radiology
Quantitative Subharmonic Breast Imaging
Philadelphia : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Pittsburgh : Univ of Pittsburgh Sch of Med
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Pittsburgh : NSABP Foundation, Inc.
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Pittsburgh : University of Pittsburgh
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Pittsburgh : Magee-Womens Hospital
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Pittsburgh : Magee Womens Hospital
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Pittsburgh : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Pittsburgh : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Pittsburgh : Hillman Cancer Center
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Pittsburgh : University of Pittsburgh
Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients
Sayre : Guthrie Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Sellersville : Bux-Mont Oncology Hematology Associates (FCCC) at Grand View Hospital
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Wynnewood : Mainline Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
East Providence : Pharma Resource Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Pawtucket : Memorial Hospital of RI
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Providence : Women & Infants Hospital
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Woonsocket : Landmark Medical Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Charleston : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Charleston :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Charleston : Charleston Hematology Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Charleston : Cancer Specialists of Charleston
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Charleston : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
View More »
Columbia : South Carolina Oncology Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Columbia : M. Francisco Gonzalez, M.D.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Columbia : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Greenville : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Greenville : Cancer Centers of the Carolinas
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Greenville : Greenville Hospital Systems
Xpress Digital Mammography System Images for Computer Aided Detection Development
Hilton Head Island : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Mt. Pleasant : Lowcountry Hematology/Onc PA
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Murrells Inlet : Coastal Carolina Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Santee : Santee Hematology/Oncology
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Sioux Falls :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Sioux Falls : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Bristol : Blue Ridge Medical Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Bristol :
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Chatanooga : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Chattanooga : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Chattanooga : Chattanooga Oncology and Hemat
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
View More »
Chattanooga : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Chattanooga :
Study Evaluating the Safety and Efficacy of Onartuzumab (Metmab) And/Or Bevacizumab in Combination With Paclitaxel in Patients With Metastatic, Triple Negative Breast Cancer
Chattanooga : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Collierville : Family Cancer Center, PLLC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Collierville : Family Cancer Center
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Cookeville : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Franklin : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Germantown : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Johnson City : McLeod Cancer & Blood Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Knoxville : Baptist Hosp East Tennessee
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Knoxville : Tennesee Cancer Specialists
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Knoxville : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Maryville : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Memphis : The West Clinic Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Memphis : The West Clinic
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Memphis :
Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer
Memphis : The West Clinic Updated
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Memphis : University of Tennessee Cancer Institute Updated
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Nashville : Sarah Cannon Research Institute
A Study of Oral Rucaparib in Patients With gBRCA Mutation Breast Cancer or Other Solid Tumor
Nashville : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Nashville : Investigational Site
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Paclitaxel, Bevacizumab, and Trastuzumab in Patients With Locally Recurrent or Metastatic Breast Cancer
Nashville :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Nashville : Sarah Cannon Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Nashville :
Dose Escalation Study of INK128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies
Nashville : Sarah canon Cancer Center
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Nashville : Tennessee Oncology Updated
GRN1005 Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases
Nashville : Vanderbilt University
IDO Inhibitor Study for Relapsed or Refractory Solid Tumors
Nashville : Nashville Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Nashville : Tennessee Oncology, PLLC
Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer
Nashville : Advantage Clinical Research
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Nashville : Tennessee Breast Specialists
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Nashville : Sarah Cannon Cancer Research Institute
Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
Nashville : Sarah Cannon Research Institute
Safety Study of MGAH22 in HER2-positive Carcinomas
Nashville : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Nashville : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Nashville : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Nashville : Investigational Site Number 1214
Study of XL147 (SAR245408) in Combination With Trastuzumab or Paclitaxel and Trastuzumab in Subjects With Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-based Regimen
Nashville : Investigational Site
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer
Nashville : Tennessee Oncology, PLLC
Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Houston : The University of Texas - M.D. Anderson Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Breast
Houston : S. R. Burzynski Clinic
Phase II Study Of Private Antineoplaston A10 And AS2-1 Capsules In Patients With Advanced Breast Cancer
Houston : S. R. Burzynski Clinic
Phase II Study Of Private Antineoplaston A10 In Combination With Low Dose Methotrexate In Patients With Advanced Breast Cancer
San Antonio : South Texas Oncology and Hematology
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
View More »
Austin : Texas Oncology-Austin Central
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Austin : US Oncology - Texas Oncology
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Austin : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Bedford : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Bedford : Texas Oncology - Bedford
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Bryan : St. Joseph Regional Cancer Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Cedar Park : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Corpus Christi : South Texas Institute of CA
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Corpus Christi : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Dallas : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Dallas :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Dallas : UT Southwestern Medical Center at Dallas
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Dallas : Texas Oncology-Dallas Presbyterian Hospital
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Dallas : Texas Oncology-Medical City Dallas
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Dallas : Texas Oncology-Baylor Charles A. Sammons Cancer Center
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Dallas : Texas Oncology-Methodist Charlton Cancer Center
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Dallas : Texas Oncology - Medical City Dallas
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Dallas : US Oncology - Texas Oncology
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Dallas : Dallas Surgical Group
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Dallas : Texas Health
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Dallas : Dallas Surgical Group
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Dallas : Texas Oncology - Baylor Charles A. Sammons Cancer Center
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Dallas : Texas Oncology - Dallas Presbyterian Hospital
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Dallas : Leading Edge Research, PA
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Dallas : Mary Crowley Cancer Research Centers (MCCRC)
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
Dallas : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Dallas : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Denton : Texas Oncology- Denton South
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
El Paso : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
El Paso : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fort Hood : Carl R. Darnall Army Medical Center
Vaccine Therapy in Treating Patients With Breast Cancer
Fort Sam Houston : Brooke Army Medical Center
Vaccine Therapy in Treating Patients With Breast Cancer
Fort Worth : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Fort Worth : Texas Oncology-Fort Worth 12th Ave.
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Fort Worth : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Forth Worth : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Ft. Worth : The Center for Cancer and Blood Disorders Updated
Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Garland : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Garland : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Houston : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Houston : Baylor College of Medicine Updated
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Houston : UT MD Anderson Cancer Center
Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis
Houston : U T M D Anderson Cancer Center
Dose-escalation Study of Oral CX-4945
Houston : MD Anderson Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Houston : Texas Oncology-Memorial City
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Houston : Texas Oncology - Memorial City
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Houston : Baylor College of Medicine Lester and Sue Smith Breast Center Updated
Extension Study of Lapatinib Plus Herceptin With or Without Endocrine Therapy
Houston : UT MD Anderson Cancer Center
Genomic Testing for Primary Breast Cancer
Houston : UT MD . Anderson Cancer Center
Longitudinal Assessment of Arthralgia and Related Symptoms in Breast Cancer
Houston : The Methodist Hospital Cancer Center
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
Houston : UT MD Anderson Cancer Center
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
Houston : UT MD Anderson Cancer Center
Personalized Treatment Selection for Dasatinib in Metastatic Breast Cancer
Houston : Texas Oncology - Memorial City
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Houston : UT MD Anderson Cancer Center Updated
Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease
Houston : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Houston : Research Site
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Houston : Memorial Hermann Hospital
The Study of Biodistribution and Dosimetry of 99mTc-Glycopeptide(99mTc-GP) in Patients With Breast Cancer
Houston : UT MD Anderson Cancer Center Updated
TKI258 for Metastatic Inflammatory Breast Cancer Patients
Houston : UT MD Anderson Cancer Center
TPI 287 in Breast Cancer Metastatic to the Brain
Houston : UT MD Anderson Cancer Center Updated
Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
Houston : University of Texas MD Anderson Cancer Center
Vaccine Therapy in Treating Patients With Breast Cancer
Kerrville : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Kyle : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Lewisville : Texas Oncology-Lewisville
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Paris : Texas Oncology-Paris
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Paris : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Plano : Plano Cancer Institute
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Plano : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Plano : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Round Rock : Scott & White Healthcare-Round Rock
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Round Rock : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
San Antonio : Cancer Care Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
San Antonio : Cancer Care Centers of South Texas
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
San Antonio : Cancer Care Centers of South Texas
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
San Antonio : Cancer Care Centers of South Texas
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
San Antonio : South Texas Accelerated Research Therapeutics (START)
Safety Study of a Liposomal Docetaxel Formulation in Patients With Solid Tumors Who Have Failed Previous Therapies
San Antonio : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
San Antonio : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
San Antonio : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
San Antonio : STOH Clinical Research
Vaccine Therapy in Treating Patients With Breast Cancer
San Antonio : University of Texas San Antonio
Xpress Digital Mammography System Images for Computer Aided Detection Development
San Marcos : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Southlake : Southlake Oncology
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Sugar Land : Texas Oncology - Sugar Land
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
Tyler : Texas Oncology-Tyler
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Tyler : US Oncology - Tyler Cancer Center
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Tyler : Texas Oncology - Tyler
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Tyler : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Waco : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
American Fork : Central Utah Clinic, PC Onc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Ogden : Northern Utah Associates
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Salt Lake City : Utah Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Salt Lake City : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Salt Lake City : University of Utah/Huntsman Cancer Center Institute
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Burlington : University of Vermont/Fletcher Allen Health Care
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Abingdon : Cancer Outreach Assoc PC
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Abingdon : Cancer Outreach Associates, P.C.
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Arlington : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Arlington : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Bent Mountain : Brabant Research, Incorporated
Natural Supplements and a Special Diet in Eliminating Growth Hormones Made Outside the Body in Patients With Early-Stage Prostate Cancer, Breast Cancer, or Uterine Cancer
View More »
Charlottesville : Virginia Breast Care
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Charlottesville : University Of Virginia Health System Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Chesapeake : Cancer Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Fairfax : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Fairfax : US Oncology - Fairfax Northern Virginia Hematology-Oncology PC
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Fairfax : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Fairfax : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Gainesville : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Gainesville : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Leesburg : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Leesburg : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Lorton : Surgical Specialists of Northern Virginia
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Mechanicsville : Virginia Cancer Institute
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Midlothian : Bon Secours Virginia Breast Center
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Newport News : Peninsula Cancer Institute
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Norfolk : Virginia Oncology Associates
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Norfolk : US Oncology - Virginia Oncology Assoc.
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Norfolk : Virginia Oncology Associates
PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations
Norfolk : Virginia Oncology Associates
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Reston : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Richlands : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Richmond : Virginia Commonwealth University
Safety Study for Short-course Accelerated, Hypofractionated Partial Breast Radiotherapy (APBI) in Women With Early Stage Breast Cancer Using the Contura MLB
Richmond : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Richmond : Virginia Cancer Center
Study of Zoledronic Acid Administered Monthly Versus Every 3 Months in Multiple Myeloma and Breast Cancer Patients Who Were Treated With Zoledronic Acid the Prior Year
Roanoke : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Salem : ImClone Investigational Site Updated
A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Patients With Breast Cancer
Winchester : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Winchester : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Woodbridge : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Woodbridge : Pfizer Investigational Site
Study Of Letrozole With Or Without PD 0332991 For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer
Bremerton : Olympic Hem and Onc Assoc
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Everett : Providence Everett Med Ctr
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Everett : Providence Everett Medical Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Everett : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Seattle : Call for Information
A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM2)
View More »
Seattle : Seattle Cancer Care Alliance
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Seattle : Seattle Cancer Care Alliance
Contrast-Enhanced Digital Mammography (CEDM) for Identifying a Change in Management of Women With Newly Diagnosed Breast Cancer
Seattle : Seattle Cancer Care Alliance
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Seattle : Swedish Cancer Institute
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Seattle : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Spokane : Rockwood Clinic
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Spokane : Rockwood Clinic
NBRST: Prospective Neo-adjuvant REGISTRY Trial
Spokane : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Tacoma : Northwest Medical Specialists
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Tacoma : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Tacoma : Madigan Army Medical Center - Tacoma
Vaccine Therapy in Treating Patients With Breast Cancer
Vancouver : Northwest Cancer Specialists, P.C.
Eribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast Cancer
Vancouver : Northwest Cancer Specialists
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Washington : Georgetown University Medical Center - Lombardi Cancer Center
National Phase 2 Breast Cancer study investigating the effectiveness and safety of ZK-Epo in women with breast cancer that has spread to other parts of their bodies
Morgantown : West Virginia University - Clinical Trials Research Unit
CIRB) NSABP B-43: A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Morgantown : West Virginia University - Clinical Trials Research Unit
CP20-0903 - An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy
Morgantown : West Virginia University - Clinical Trials Research Unit
E2108: A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer
Morgantown : West Virginia University - Clinical Trials Research Unit
NSABP-B47 - A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Morgantown : West Virginia University - Clinical Trials Research Unit
S1007: A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
View More »
Morgantown : West Virginia University Hospitals
Combination of Weekly Paclitaxel With Neratinib and Trastuzumab in Women With Metastatic HER2-positive Breast Cancer
Morgantown : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Morgantown : ImClone Investigational Site
Study of IMC-18F1 or Ramucirumab DP in Combination With Capecitabine or Capecitabine on Previously Treated Breast Cancer Patients
Wheeling : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Appleton : Valley Hematology & Oncology
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Glendale : Oncology Alliance
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Madison : University Of Wisconsin Updated
Study of BMS-754807 Combined With Letrozole or BMS-754807 Alone in Patients With Hormone Receptor-Positive Breast Cancer and Resistance to Non-Steroidal Aromatase Inhibitors
Milwaukee : Medical College of Wisconsin
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
Milwaukee : Clinical Cancer Center
Efficacy and Safety of Zoledronic Acid ( Every 4 Weeks vs. Every 12 Weeks) in Patients With Documented Bone Metastases From Bone Cancer
View More »
Milwaukee : Aurora Sinai Medical Center
Prediction of Response to Neoadjuvant Chemotherapy in Women With Operable Breast Cancer
Racine : All Saints Cancer Center
An Observational Study of Treatment Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer (VIRGO)
Racine : Pfizer Investigational Site
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
Buenos Aires :
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Breast Cancer Progressing After First-Line Therapy With Avastin and Chemotherapy (TANIA)
Buenos Aires : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Buenos Aires :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Buenos Aires : Instituto Saint Dennis
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
Capital Federal :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
View More »
Cordoba : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Cordoba : Novartis Investigative Site
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
La Pampa :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
La Plata : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Mendoza : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Neuquen : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Provincia de Santa Fe : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Quilmes : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Quilmes : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Rosario : Updated
A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy
Rosario : Novartis Investigative Site
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
San Martin : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
San Miguel de Tucuman :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
San Miguel de Tucuman :
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
San Miguel de Tucuman : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Adelaide :
A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE)
Bedford Park : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Bentleigh East : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Camperdown : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Caringbah : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
View More »
East bentleigh : Novartis Investigative Site
Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer
East Melbourne : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Fitzroy : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Footscray : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Frankston : Local Institution
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
Frankston : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Geelong : Local Institution
Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer
Geelong : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Heidelberg : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Kogarah : Research Site
Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)
Kogarah, Sydney : Cancer Care Centre, St George Hospital
Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers
